

After filing the previous Response, and while preparing a patent application based on related technology, the following information was brought to the attention of the undersigned Attorney for Applicant.

Scientist employees of International Bioimmune Systems, assignee of the above-identified application, found that a chimeric version of monoclonal antibody 31.1., claimed in the above-identified application, binds to an antigen well known in the literature, and designated A33. Monoclonal antibody that binds to A33 is also well known in the literature. Patents relating to A33 and A33-directed antibody and methods of treatment have been issued. Applicants submit herewith a Second Declaration of Dr. Jeffrey Fasick Under 37 C.F.R. §1.132, averring to this fact. Applicants also submit herewith an Information Disclosure Statement which provides references relating to A33 antigen and antibodies binding thereto. It is respectfully requested that these references be considered by the Examiner and made of record. Applicants will provide a Supplemental Reissue Declaration referring to these materials if required by the Examiner.

Respectfully submitted,
BAKER BOTTS L.L.P.

By: _____

Lisa B. Kole
Patent Office Reg. No. 35,225
Attorney for Applicant

30 Rockefeller Plaza
New York, NY 10012-4498
(212)-408-2500